MRSH Contingent consideration fair value adjustments decreased by 47.4% to $10.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 300.0%, from -$5.00M to $10.00M. Over 2 years (FY 2022 to FY 2025), Contingent consideration fair value adjustments shows an upward trend with a 75.6% CAGR.
Increases often signal that acquired assets are performing better than expected, requiring higher future payouts, while decreases may suggest lower-than-anticipated success in R&D milestones.
This reflects the periodic adjustments to the fair value of earn-out provisions or milestone payments related to past bu...
Standard for R&D-heavy firms that frequently acquire biotech companies with milestone-based deal structures.
operating_business_combination_contingent_consideration__7f0be7| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $10.00M | $0.00 | -$9.00M | $11.00M | $8.00M | -$31.00M | -$8.00M | -$67.00M | $0.00 | -$8.00M | -$5.00M | $16.00M | $7.00M | $19.00M | $10.00M |
| QoQ Change | — | -100.0% | — | +222.2% | -27.3% | -487.5% | +74.2% | -737.5% | +100.0% | — | +37.5% | +420.0% | -56.3% | +171.4% | -47.4% |
| YoY Change | — | — | — | — | -20.0% | — | -200.0% | -116.1% | — | — | +37.5% | +123.9% | — | +337.5% | +300.0% |